All fact sheets and treatment class tables on the WFH Shared Decision-Making (SDM) Tool have been updated to include new evidence for 2025, providing users with accurate, accessible, and evidence-based resources when considering treatment options.
Highlights of the latest release include:
- Addition of ultra–long half-life (UHL) factor replacement therapy, antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl, for hemophilia A. This new therapy extends the duration of factor activity, keeping patients in the normal or near-normal FVIII activity range for longer periods. This reduces the time spent in low-factor or high-risk zones as well as the frequency of infusions needed, expanding treatment options for people with hemophilia A.
- Addition of three new rebalancing agents: marstacimab, concizumab and fitusiran. Rather than replacing missing factor directly, these therapies act by rebalancing the clotting system. By incorporating the latest evidence on marstacimab, concizumab, and fitusiran, the WFH SDM Tool now offers comprehensive information on this fast-developing treatment class.
Information on antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl, marstacimab, concizumab, and fitusiran are now included alongside other established therapies, giving people with hemophilia and clinicians a more comprehensive overview of the choices available. With fact sheets and comparative information on UHL and rebalancing therapies now fully integrated, the tool reflects the latest evidence and evolving treatment landscape.
The updated WFH SDM Tool is currently available in six languages—English, French, Spanish, Japanese, German, and Dutch—with Italian, Czech, Croatian, Arabic, and Danish planned for the near future. This ensures that users around the world can access the same high-quality information in their preferred language. The WFH is committed to expanding the tool’s reach through additional translations, supporting its vision of making shared decision-making a global standard of care.
Shared decision-making is central to personalized hemophilia care. By regularly updating the SDM Tool with new treatment classes, the WFH continues to help people with hemophilia and their healthcare team work together to identify treatment options that best align with individual needs, values, and contexts.
The WFH encourages all members of the hemophilia community to explore the updated tool and use it to support meaningful conversations about care.